Tickers

1. Composite Trajectory Verdict

Given PRVA's acquisitive growth model and high revenue growth with thin operating margins, the income statement matters most for assessing operating leverage, while cash flow is critical due to working capital dynamics from provider liability and receivables.

Composite Trajectory: Mixed

Revenue and operating income show consistent year-over-year growth across both annual and quarterly periods (FY 2025 revenue +22.3% to $2.12B; Q2 2026 revenue +21.4% to $632.6M; YTD 2026 revenue +23.5% to $1.24B). Operating income more than doubled in FY 2025 (+101.6% to $34.2M) and YTD 2026 (+124.4% to $19.2M). However, operating cash flow deteriorated sharply in the first half of 2026 (YTD 2026: -$48.4M vs YTD 2025: -$16.1M) driven by a $172.4M increase in accounts receivable versus only a $71.0M increase in provider liability. The balance sheet shows declining cash ($479.7M to $412.2M in six months) and rising receivables, offset by growing equity and no drawn debt.

2. Red Flags

• Operating cash flow turned significantly more negative in YTD 2026 (-$48.4M) versus YTD 2025 (-$16.1M) despite net income rising 44% to $13.4M, due to a $172.4M increase in accounts receivable and only a $71.0M increase in provider liability (10-Q 2026-06-30, Condensed Statements of Cash Flows).
• Accounts receivable grew 43% in six months (Dec 2025: $400.9M to Jun 2026: $574.2M) while revenue grew 23.5% YTD, indicating potential collection timing issues or revenue recognition acceleration (10-Q 2026-06-30, Condensed Balance Sheets; 10-Q 2026-06-30, Condensed Statements of Operations).
• Provider liability growth slowed to $71.0M in YTD 2026 from $81.2M in YTD 2025 despite higher FFS and VBC revenue, reducing a key working capital offset (10-Q 2026-06-30, Condensed Statements of Cash Flows).
• Net income attributable to Privia declined in Q1 2026 ($3.1M) versus Q1 2025 ($4.2M) despite 25.8% revenue growth, due to higher operating expenses and a higher effective tax rate (10-Q 2026-03-31, Condensed Statements of Operations).
• Effective tax rate spiked to 48.4% in Q2 2026 from 32.8% in Q2 2025, driven by unfavorable equity compensation tax impacts (10-Q 2026-06-30, Note 8).
• Cash decreased $67.5M in YTD 2026 while the company repurchased $11.4M of non-controlling interest and spent $11.4M on acquisitions (10-Q 2026-06-30, Condensed Statements of Cash Flows).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Revenue has grown consistently: FY 2025 +22.3% to $2.12B (10-K 2025-12-31, Consolidated Statements of Operations); Q2 2026 +21.4% to $632.6M; Q1 2026 +25.8% to $603.8M; YTD 2026 +23.5% to $1.24B (10-Q 2026-06-30, Condensed Statements of Operations). Operating income expanded at a faster rate: FY 2025 +101.6% to $34.2M; Q2 2026 +252.9% to $11.8M; YTD 2026 +124.4% to $19.2M. Net income attributable to Privia rose FY 2025 +59.3% to $22.9M and YTD 2026 +75.4% to $12.1M, though Q1 2026 dipped to $3.1M from $4.2M. FFS-patient care remains the largest revenue component (64-65% of total) and grew 18.7% in FY 2025 and ~25% in recent quarters. VBC revenue share stabilized around 29% in 2025-2026 after dropping from 33.8% in 2023. Gross profit margin (Care Margin/revenue) declined slightly to ~21% in recent periods from 23.3% in FY 2024, but Platform Contribution Margin improved to ~52% in H1 2026 from ~49.5% in H1 2025 (10-Q 2026-06-30, MD&A).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Annual operating cash flow improved from $80.8M (FY 2023) to $109.3M (FY 2024) to $163.4M (FY 2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). However, the most recent comparable period (YTD 2026 vs YTD 2025) shows a sharp reversal: net cash used in operating activities was -$48.4M in YTD 2026 versus -$16.1M in YTD 2025 (10-Q 2026-06-30, Condensed Statements of Cash Flows). The deterioration was driven by a $172.4M increase in accounts receivable (vs $121.5M in YTD 2025) and a smaller provider liability build ($71.0M vs $81.2M). Investing outflows moderated to -$11.5M YTD 2026 from -$89.1M YTD 2025 as acquisition spending slowed. Financing turned negative (-$7.6M) due to an $11.4M non-controlling interest repurchase, versus +$4.1M in YTD 2025. Cash on hand fell from $479.7M (Dec 2025) to $412.2M (Jun 2026).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew from $1.14B (Dec 2024) to $1.37B (Dec 2025) to $1.49B (Jun 2026) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Balance Sheets). Cash and equivalents peaked at $491.1M (Dec 2024) then declined to $479.7M (Dec 2025) and $412.2M (Jun 2026). Accounts receivable rose steadily: $316.2M (Dec 2024) → $400.9M (Dec 2025) → $574.2M (Jun 2026). Provider liability increased: $364.6M → $469.5M → $541.4M over the same periods. Goodwill and intangibles grew with acquisitions (Evolent ACO, PMG AZ, PMG NJ) from $251.4M (Dec 2024) to $425.8M (Dec 2025) to $434.4M (Jun 2026). Total stockholders' equity rose consistently: $683.4M (Dec 2024) → $790.9M (Dec 2025) → $838.1M (Jun 2026). No debt is drawn on the $250M revolving facility (10-Q 2026-06-30, Note 7). The current ratio (current assets/current liabilities) was ~1.6x at Jun 2026 (1025.3M/634.4M) versus ~1.6x at Dec 2025 (911.0M/568.5M).

6. Data Gaps

• Quarterly cash flow statements for Q1 2026 and Q2 2026 individually (only YTD six-month data provided in 10-Q 2026-06-30).
• Full-year 2026 revenue and expense run-rate expectations (not in filings).
• Breakdown of provider liability between FFS and capitated components for quarterly periods.
• Detailed revenue by market or payer for quarterly periods (only top three payer concentrations provided).
• Q3 2025 and Q4 2025 quarterly financial statements (only FY 2025 annual and Q1/Q2 2026 quarterly provided).
• Capital expenditure details beyond business acquisitions.
• Terms and maturity schedule of the revolving credit facility beyond the 2031 extension.